©2025 Stanford Medicine
Study in Subjects With Small Primary Choroidal Melanoma
Not Recruiting
Trial ID: NCT03052127
Purpose
The primary objective is to assess the safety, immunogenicity and efficacy of one of three dose levels and repeat dose regimens of Light-activated AU-011 and one or two laser applications for the treatment of subjects with primary choroidal melanoma.
Official Title
A Phase 1B/2 Open-Label, Ascending Single and Repeat Dose Clinical Trial Designed to Evaluate the Safety and Efficacy of Light-activated AU-011 for the Treatment of Subjects With Small Primary Choroidal Melanoma
Stanford Investigator(s)
Prithvi Mruthyunjaya, MD, MHS
Alan Adler Professor of Ophthalmology and Professor, by courtesy, of Radiation Oncology
Eligibility
Inclusion Criteria:
* Diagnosis of choroidal melanoma
Exclusion Criteria:
* Have known contraindications or sensitivities to the study drug
Intervention(s):
drug: Light-activated AU-011
device: Laser Activation
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Mariana Nunez
650-497-7846